Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03838926 · ClinicalTrials.gov registry record · Phase 1
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
A Phase 1 study of Relapsed or Refractory Hematologic Malignancies, sponsored by Vanda Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 11
- Study locations
NCT03838926: Recruiting Phase 1 study of Relapsed or Refractory Hematologic Malignancies, sponsored by Vanda Pharmaceuticals.
NCT03838926 is a Phase 1 study of Relapsed or Refractory Hematologic Malignancies that is actively recruiting participants, run by Vanda Pharmaceuticals. The registered enrollment target is 42 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower). The trial reports 11 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03838926, a Phase 1 study of Relapsed or Refractory Hematologic Malignancies, is actively recruiting participants, sponsored by Vanda Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 11
- Study locations
Study Summary
The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.
Primary Outcome
Measured by spontaneous reporting of adverse events (AEs)
Conditions Studied
Interventions
- DRUG Trichostatin A
Study Locations (11)
Other
- Vanda Investigational Site - Biała Podlaska
- Vanda Investigational Site - Katowice
- Vanda Investigational Site - Krakow
- Vanda Investigational Site - Opole
- Vanda Investigational Site - Skorzewo
- Vanda Investigational Site - Warsaw
- Vanda Investigational Site - Wroclaw
District of Columbia
- Vanda Investigational Site - Washington D.C.
Indiana
- Vanda Investigational Site - Lafayette
New Jersey
- Vanda Investigational Site - Hackensack
Washington
- Vanda Investigational Site - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-09-27 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
What NCT03838926 shows while recruiting
NCT03838926 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Relapsed or Refractory Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which Trichostatin A is the first listed.
NCT03838926 lists 11 locations in 5 states (Other, District of Columbia, Indiana).
Frequently Asked Questions
What is clinical trial NCT03838926 about?
NCT03838926 is a clinical study titled "Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies". The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.
What is the current status of trial NCT03838926?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2018-09-27. Estimated completion is 2027-12.
What conditions does trial NCT03838926 study?
This clinical trial studies the following conditions: Relapsed or Refractory Hematologic Malignancies.
What interventions are being tested in trial NCT03838926?
The interventions under investigation include: Trichostatin A (DRUG).
Who is sponsoring clinical trial NCT03838926?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03838926 being conducted?
This trial has 11 study locations across District of Columbia, Indiana, New Jersey, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03838926's enrollment target sits among peer trials
42 1106th of 2000 higher than 876 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI